Cristin

2019
1.	Aasebø, Elise; Berven, Frode; Bartaula-Brevik, Sushma; Stokowy, Tomasz; Hovland, Randi; Vaudel, Marc; Døskeland, Stein Ove; Mc Cormack, Emmet; Batth, Tanveer S; Olsen, Jesper V; Bruserud, Øystein; Selheim, Frode; Hernandez-Valladares, Maria. Proteome and phosphoproteome changes associated with prognosis in acute myeloid leukemia. bioRxiv 2019 HAUKELAND UiB Untitled

2.	Aasebø, Elise; Hernandez-Valladares, Maria; Selheim, Frode; Berven, Frode; Brenner, Annette; Bruserud, Øystein. Proteomic profiling of primary human acute myeloid leukemia cells does not reflect their constitutive release of soluble mediators. Proteomes 2019 ;Volum 7.(1) s. 1-10 HAUKELAND UiB Untitled

3.	Bjørnstad, Ronja; Aesoy, Reidun; Bruserud, Øystein; Brenner, Annette; Giraud, Francis; Dowling, Tara Helen; Gausdal, Gro; Moreau, Pascale; Doskeland, Stein Ove; Anizon, Fabrice; Herfindal, Lars. A kinase inhibitor with anti-Pim kinase activity is a potent and selective cytotoxic agent toward acute myeloid leukemia. Molecular Cancer Therapeutics 2019 ;Volum 18.(3) s. 567-578 SAV UiB Untitled

4.	Brattås, Marte Karen; Reikvam, Håkon; Tvedt, Tor Henrik Anderson; Bruserud, Øystein. Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Expert Opinion on Investigational Drugs 2019 ;Volum 28.(5) s. 411-420 HVprivate UiB HAUKELAND Untitled

5.	Brattås, Marte Karen; Reikvam, Håkon; Tvedt, Tor Henrik Anderson; Bruserud, Øystein. Dasatinib is an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Expert Opinion on Investigational Drugs 2019 HVprivate UiB HAUKELAND Untitled

6.	Brattås, Marte Karen; Reikvam, Håkon; Tvedt, Tor Henrik Anderson; Bruserud, Øystein. Precision medicine for TP53-mutated acute myeloid leukemia. Expert Review of Precision Medicine and Drug Development 2019 ;Volum 4.(5) s. 263-274 HVprivate UiB HAUKELAND Untitled

7.	Brenner, Annette; Aasebø, Elise; Hernandez-Valladares, Maria; Selheim, Frode; Berven, Frode; Grønningsæter, Ida Sofie; Bartaula-Brevik, Sushma; Bruserud, Øystein. The capacity of long-term in vitro proliferation of acute myeloid leukemia cells supported only by exogenous cytokines is associated with a patient subset with adverse outcome. Cancers 2019 ;Volum 11:73. s. 1-22 HAUKELAND UiB Untitled

8.	Brenner, Annette; Bruserud, Øystein. Functional toll-like receptors (TLRs) are expressed by a majority of primary human acute myeloid leukemia cells and inducibility of the TLR signaling pathway is associated with a more favorable phenotype. Cancers 2019 ;Volum 11.(7) UiB HAUKELAND Untitled

9.	Forthun, Rakel Brendsdal; Hellesøy, Monica; Sulen, Andre; Kopperud, Reidun Kristin; Sjøholt, Gry; Bruserud, Øystein; McCormack, Emmet; Gjertsen, Bjørn Tore. Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology 2019 ;Volum 145.(7) s. 1729-1749 UiB HAUKELAND HVL Untitled

10.	Grønningsæter, Ida Sofie; Fredly, Hanne Kristin; Gjertsen, Bjørn Tore; Hatfield, Kimberley Joanne; Bruserud, Øystein. Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy.. Cells 2019 ;Volum 8.(10) HAUKELAND UiB VV Untitled

11.	Leufven, Eva; Bruserud, Øystein. Immunosuppression and immunotargeted therapy in acute myeloid leukemia - The potential use of checkpoint inhibitors in combination with other treatments. Current Medicinal Chemistry 2019 ;Volum 26.(28) s. 5244-5261 UiB HAUKELAND Untitled

12.	Nepstad, Ina. The PI3K-Akt-mTOR intracellular signaling pathway in human acute myeloid leukemia. : Universitetet i Bergen 2019 (ISBN 978-82-308-3529-6) UiB Untitled

13.	Nepstad, Ina; Hatfield, Kimberley Joanne; Grønningsæter, Ida Sofie; Aasebø, Elise; Hernandez-Valladares, Maria; Hagen, Karen Marie; Rye, Kristin Paulsen; Berven, Frode; Selheim, Frode; Reikvam, Håkon; Bruserud, Øystein. Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells.. Signal Transduction and Targeted Therapy 2019 HAUKELAND UiB Untitled

14.	Reikvam, Håkon; Aasebø, Elise; Brenner, Annette; Bartaula-Brevik, Sushma; Grønningsæter, Ida Sofie; Forthun, Rakel Brendsdal; Hovland, Randi; Bruserud, Øystein. High constitutive cytokine release by primary human acute myeloid leukemia cells is associated with a specific intercellular communication phenotype. Journal of Clinical Medicine 2019 ;Volum 8.(7) UiB HAUKELAND Untitled

15.	Reikvam, Håkon; Dalgaard, Jakob; Johansen, Silje; Tvedt, Tor Henrik Anderson; Bruserud, Øystein. Behandling av akutt myelogen leukemi hos eldre. Tidsskrift for Den norske legeforening 2019 VV HAUKELAND UiB Untitled

16.	Rundgren, Ida Marie; Ersvær, Elisabeth; Ahmed, Aymen B; Ryningen, Anita; Bruserud, Øystein. Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation – a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients. BMC Immunology 2019 ;Volum 20.(1) s. 1-13 UiB HVL HAUKELAND Untitled

17.	Skaadel, Hanne; Bruserud, Øystein. Thrombotic complications in adult patients with severe single coagulation factor or platelet defects-\|an overview. Expert Review of Hematology 2019 ;Volum 12.(2) s. 119-128 HAUKELAND UiB Untitled